Ultragenyx Pharmaceutical Inc.

RARE Healthcare Biotechnology

Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

14.54 0.63 −4.15%
Market cap
$1.5B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
5/9
Altman Z
−3.57
Beneish M
−2.68
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
5 4 4 3 3 5 4 4 — —
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
3.37 6.80 8.16 8.76 16.22 31.08 23.30 42.03 767.05 0.00
Altman Z-Score
(3.57) (2.28) (2.05) (1.56) 3.73 7.35 0.89 8.85 6.91 22.93
Altman Z″-Score (non-manufacturers)
(9.61) (8.70) (7.75) (5.73) (1.60) 1.86 (0.88) 1.72 (3.63) 5.33
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(22.72) (48.00) (42.10) (35.23) (104.91) (134.87) (33.54) (38.75) (25.57) (58.09)
Beneish M-Score
(2.68) (2.55) (2.08) (3.27) (2.38) (1.91) (0.53) 14.07 — —
P/B ratio
0.00 14.93 12.86 9.03 6.18 7.30 3.70 3.55 5.46 5.84
Price to Tangible BV
0.00 115.37 54.69 21.51 7.63 8.60 5.03 4.97 10.59 5.84
EV/Sales
2.36 5.71 6.83 6.70 14.12 26.64 16.02 33.10 681.09 0.00
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(3.41) (7.72) (6.24) (6.40) (14.65) (54.62) (4.81) (5.87) (7.32) (14.84)
EV/FCF
(3.26) (7.37) (5.68) (4.62) (12.05) (41.00) (4.49) (5.78) (7.24) (13.95)
Quick Ratio
2.18 2.13 2.32 3.02 4.24 6.46 7.63 6.32 3.37 6.33
Current Ratio
2.48 2.38 2.61 3.38 4.72 6.83 8.24 6.99 3.80 6.67
Net Debt/EBITDA
1.35 1.19 1.04 1.19 2.05 3.79 1.79 1.30 0.73 1.59
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.44 0.37 0.29 0.24 0.21 0.19 0.11 0.09 0.01 0.00
Operating CF/Net income
0.81 0.73 0.78 0.54 0.75 0.71 0.86 1.47 0.84 0.65
Capex/Depreciation
(0.68) (0.87) (3.62) (6.99) (3.68) (3.35) (10.68) (0.24) (0.37) (1.23)
Interest Coverage
(8.63) (8.51) (8.62) (15.09) (12.97) (9.92) (373.72) (38.92) (80.74) (65.45)
ROE
(657.14%) (214.55%) (193.34%) (110.96%) (43.72%) (20.64%) (63.79%) (39.83%) (70.48%) (48.93%)
ROA
(37.89%) (38.01%) (39.98%) (46.12%) (27.67%) (12.89%) (43.42%) (32.65%) (58.59%) (44.70%)
ROIC
0.00% 0.00% 0.00% 0.00% (130.83%) 0.00% 0.00% (155.57%) (138.02%) (167.73%)
Return on Tangible Assets
(70.90%) (77.00%) (81.77%) (80.17%) (55.61%) (15.82%) (50.85%) (42.25%) (137.08%) (68.59%)
Average Days of Receivables
85.69 79.52 61.72 40.63 29.53 31.10 115.59 90.30 722.73 0.00
Research and Development Expense of Revenue
111.44% 124.64% 149.31% 194.26% 141.48% 152.04% 344.56% 570.93% 8,868.45% 137,747.37%
Selling, General and Administrative Expense of Revenue
51.86% 57.32% 71.43% 76.55% 62.60% 67.50% 155.74% 248.03% 3,825.00% 48,824.06%
Intangible Assets out of Total Assets
0.14 0.15 0.14 0.13 0.12 0.10 0.15 0.24 0.38 0.00
Share Based Compensation of Revenue
22.73% 28.21% 31.11% 35.88% 29.87% 31.63% 79.06% 155.56% 2,603.91% 36,322.56%
Graham Net Nets
(0.29) (0.11) (0.14) (0.10) 0.05 0.08 0.15 0.19 0.08 0.12
Graham Number
10.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(25.39%) (15.07%) (17.29%) (22.21%) (7.98%) (2.26%) (16.67%) (8.97%) (14.42%) (8.86%)
Free Cash Flow Yield
(21.47%) (11.40%) (14.74%) (16.55%) (7.22%) (2.09%) (15.32%) (13.61%) (12.26%) (6.18%)
Revenue per Share
6.83 6.19 5.90 5.20 5.18 4.45 1.83 1.03 0.06 0.00
Operating CF per Share
(4.73) (4.57) (6.46) (5.44) (5.00) (2.17) (6.10) (5.84) (5.98) (4.07)
Capex per Share
(0.21) (0.22) (0.64) (2.09) (1.08) (0.72) (0.44) (0.08) (0.07) (0.26)
Free Cash Flow per Share
(4.94) (4.80) (7.10) (7.53) (6.07) (2.89) (6.54) (5.92) (6.05) (4.32)
Cash per Share
6.90 6.74 7.85 10.70 10.92 19.75 13.35 9.24 5.52 9.64
Shareholders Equity per Share
(0.81) 2.82 3.75 5.04 13.61 18.97 11.56 12.23 9.03 11.97
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(0.81) 2.82 3.75 5.04 13.61 18.97 11.56 12.23 9.03 11.97
Free Cash Flow
(487.00) (434.00) (522.00) (526.59) (411.79) (176.12) (370.21) (294.64) (256.64) (171.16)
Working Capital
567.00 473.00 451.75 622.69 675.24 1,105.70 747.72 447.64 198.57 341.44
Capital Expenditures
(21.00) (20.00) (47.00) (146.12) (73.09) (43.90) (24.83) (4.08) (2.79) (10.19)
Net Current Asset Value
(661.00) (431.00) (483.41) (309.05) 256.77 690.12 369.29 411.72 162.28 335.04
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.03 0.04 0.11 0.40 0.21 0.16 0.24 0.08 1.07 76.60
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.13 0.09 0.04 0.08 0.14 0.18 0.05 0.84 0.34 0.48
Cash ROIC
(81.17%) (50.17%) (61.22%) (47.86%) (24.77%) (7.48%) (26.28%) (27.57%) (41.53%) (20.01%)
Accounts Receivable Turnover
4.81 5.73 7.63 10.55 13.64 9.69 4.55 5.75 0.99 0.00
Accounts Payable Turnover
3.11 1.90 1.05 0.94 1.07 0.48 0.72 0.11 0.00 0.00
Inventory Turnover
2.25 1.95 1.48 1.32 1.09 0.50 0.97 0.29 0.00 —
Average Days of Payables
103.81 184.87 341.59 557.73 390.77 769.60 521.53 3,909.58 3,243,390.00 0.00
Days of Inventory on Hand
174.13 213.31 275.53 344.97 370.08 777.05 467.84 2,250.20 276,305.00 —
Average Receivables
140.00 97.70 56.92 34.44 25.76 27.97 22.79 8.96 2.64 —
Average Payables
35.00 40.56 42.69 30.21 15.03 12.90 12.57 10.58 7.13 4.15
Average Inventory
48.50 39.48 30.37 21.50 14.64 12.30 9.31 3.91 4.00 —
Average Assets
1,517.50 1,497.01 1,518.23 1,533.92 1,640.98 1,447.53 927.53 605.16 515.69 550.10
Average Common Equity
87.50 265.21 313.95 637.53 1,038.47 904.07 631.34 496.18 428.71 502.53

Fold the line items

Columns are period end dates